These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17087306)

  • 1. [Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].
    Tamura H; Mokuno H; Daita H
    Nihon Rinsho; 2006 Nov; 64(11):2119-25. PubMed ID: 17087306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glycemic control and cardiovascular benefit: What do we know today?].
    Hanefeld M; Schönauer M; Forst T
    Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of pioglitazone, one of TZDs, on IGT-patients].
    Kobayashi M
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():462-70. PubMed ID: 15779423
    [No Abstract]   [Full Text] [Related]  

  • 5. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Glinide(s), sulfonylurea(s)].
    Arakawa M; Hirose T
    Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
    Pfützner A; Schneider CA; Forst T
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):445-59. PubMed ID: 16918264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Early intervention in diabetic patients compensates "cell ignorance"].
    MMW Fortschr Med; 2002 May; 144(21):52-3. PubMed ID: 12134427
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Insulin resistance and atherosclerosis. Controlling diabetes on 2 fronts].
    MMW Fortschr Med; 2003 Sep; 145(37):65. PubMed ID: 14584452
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.
    Ajjan RA; Grant PJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):147-58. PubMed ID: 17160909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
    Ríos-Vázquez R; Marzoa-Rivas R; Gil-Ortega I; Kaski JC
    Am J Cardiovasc Drugs; 2006; 6(4):231-42. PubMed ID: 16913824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J
    Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
    Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
    Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide.
    Belcher G; Lambert C; Goh KL; Edwards G; Valbuena M
    Int J Clin Pract; 2004 Sep; 58(9):833-7. PubMed ID: 15529516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Zimmet P; Collier G
    Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications.
    Molavi B; Rassouli N; Bagwe S; Rasouli N
    Vasc Health Risk Manag; 2007; 3(6):967-73. PubMed ID: 18200815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.